Global Tocilizumab Market – Industry Trends and Forecast to 2030

Global Tocilizumab Market, By Product Type (Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%), Dosage (Injection, Solution, Concentrate), Route of Administration (Subcutaneous, Intravenous), Application (Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), Rheumatoid Arthritis (RA).), Demographic (Adult, Pediatric, Geriatric), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.

Tocilizumab Market Analysis and Size

Tocilizumab is a humanized IgG1 monoclonal antibody used for the treatment of cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis (GCA), and rheumatoid arthritis (RA). It works by blocking the binding of IL-6.

The market drivers include the increasing geriatric population, rise in the prevalence of autoimmune and inflammatory conditions, growing concentration of major pharmaceutical companies. Growing government initiatives and rising awareness are the factors that will expand the global tocilizumab market. Rising R&D activities, clinical trials, and growing medical research will provide beneficial opportunities for the global tocilizumab market in the forecast period. Tocilizumab increase the cholesterol level, which affects liver function test. It also shows some side effects such as hypercholesterolemia, high blood pressure, mouth ulcers, allergic reactions, dizziness, upper respiratory tract infections, and other severe conditions. All these factors hamper the market growth and will further challenge the global tocilizumab market in the forecast period mentioned above.

The product type segment is dominating the global tocilizumab market due to the rise in patient population and tocilizumab is approved for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. These factors are further stimulated the market growth.

Data Bridge Market Research analyses that the tocilizumab market, valued at USD 72.37 million in 2022, will reach USD 181.75 million by 2030, growing at a CAGR of 12.20% during the forecast period of 2023 to 2030. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Tocilizumab Market Scope and Segmentation

Market Definition

Tocilizumab is a monoclonal antibody that acts against the interleukin-6 (IL-6) receptor, primarily used for the treatment of inflammatory conditions such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome induced by CAR-T therapy. Tocilizumab has demonstrated significant efficacy in reducing disease activity and improving outcomes in patients with sJIA. The market encompasses the manufacturing, distribution, and sales of Tocilizumab across various regions worldwide, driven by the demand for effective anti-inflammatory therapies and advancements in targeted treatments for specific diseases.

Tocilizumab Market Dynamics

Drivers

• Increasing Prevalence of Rheumatoid Arthritis and Other Inflammatory Conditions

The growing incidence of rheumatoid arthritis, systemic juvenile idiopathic arthritis, and other inflammatory conditions is driving the demand for drugs such as tocilizumab. These diseases require effective anti-inflammatory treatments, and tocilizumab has shown positive clinical outcomes in managing these conditions.

• Growing Adoption of Targeted Therapies

Tocilizumab belongs to a class of targeted therapies known as monoclonal antibodies. These therapies are gaining popularity due to their specificity and effectiveness in treating specific diseases. The increasing adoption of targeted therapies, including tocilizumab, is contributing to the growth of the market.

• Expanding Indications and Label Expansions

Tocilizumab is being explored for its efficacy in treating various diseases beyond its current approved indications. Ongoing clinical trials and research are investigating its potential use in conditions such as COVID-19-related cytokine storm and other inflammatory disorders. Positive results from these studies could lead to label expansions, further driving the demand for tocilizumab.

Opportunities

• Increasing Focus on Personalized Medicine

The shift towards personalized medicine, tailoring treatment approaches based on individual patient characteristics, presents an opportunity for tocilizumab. More emphasis is placed on targeted therapies and precision medicine, tocilizumab's specificity in blocking the interleukin-6 (IL-6) pathway makes it a valuable option for personalized treatment strategies.

• Growing Biologics Market

The overall growth of the biologics market, driven by factors such as increasing R&D investments, technological advancements, and patient preference for biologics, positively impacts the tocilizumab market. Tocilizumab benefits from the broader trends shaping the biologics market as a biologic agent.

Restraints/Challenges

• High Cost of Treatment

The high cost associated with tocilizumab treatment can be a restraint for market growth. The expense of the drug and the need for ongoing therapy can limit access and affordability for some patients and healthcare systems.

• Competition from Existing and Emerging Biologic Therapies

Tocilizumab faces competition from other biologic therapies used in the treatment of inflammatory conditions. The emergence of new drugs and potential biosimilars, manufacturers of Tocilizumab need to navigate a competitive landscape and differentiate their product to maintain market share.

This tocilizumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Tocilizumab Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2022, Genentech, a Roche Group company, announced that the FDA approved Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients receiving systemic corticosteroids and requiring non-invasive or invasive mechanical ventilation, supplemental oxygen, or extracorporeal membrane oxygenation (ECMO). Actemra is the first FDA-approved monoclonal antibody for the treatment of COVID-19, and it is administered as a single 60-minute IV infusion.
• In September 2022, The European Medicines Agency (EMA) approved the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA (tocilizumab).
• In April 2021, Novartis agreed on a preliminary contract with Roche to reserve capacity for the production of API for Roche's Actemra/RoActemra (tocilizumab). This rheumatoid arthritis treatment has been tested in various clinical trials investigating the safety and efficacy of COVID-19-associated pneumonia.

Global Tocilizumab Market Scope

The global tocilizumab market is segmented on the basis of product type, dosage, route of administration, application, demographic, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Min purity less than 98%
• Min purity 98%-99%
• Min purity more than 99%

Dosage

• Injection
• Solution
• Concentrate

 Route of administration

• Subcutaneous
• Intravenous

Application

• Cytokine release syndrome (CRS)
• Systemic juvenile idiopathic arthritis (sjia)
• Giant cell arteritis (GCA)
• Rheumatoid arthritis (RA)

Demographic

• Adult
• Geriatric
• Pediatric

End-UserS

• Hospitals
• Clinics
• Others

 Distribution channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

Tocilizumab Market Regional Analysis/Insights

Global tocilizumab market is analyzed and market size information is provided by the country, product type, dosage, route of administration, application, demographic, end-users, and distribution channel as referenced above.

The countries covered in the global tocilizumab market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the tocilizumab market due to the presence of major key players, continuous technological development, well-developed healthcare sector, increasing prevalence of disease, and increasing awareness towards health in this region.

 Asia-Pacific is expected to grow during the forecast period due to the increasing research and development activities, rising investment in the healthcare sector, increasing demand for treatment, and increasing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The tocilizumab market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for tocilizumab market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the tocilizumab market. The data is available for historic period 2015-2020.

Competitive Landscape and Tocilizumab Market Share Analysis

The Tocilizumab Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the tocilizumab market are:

• Bio-Rad Laboratories, Inc. (U.S.)
• SimSon Pharma Limited (India)
• Selleck Chemicals (U.S.)
• Bio-Techne (U.S.)
• Biosynth (U.S)
• BioVision Inc.(U.S.)
• CLEARSYNTH LABS (U.S.)
• AbMole BioScience (U.S.)
• Biorbyt Ltd.(U.K.)
• Bloomberg Finance L.P. (U.S)
• LifeSpan BioSciences, Inc (U.S.)